论文部分内容阅读
我们的工作表明,小鼠骨髓有核细胞微核测定对辐射防护药的筛选是一个灵敏、简便的新指标。在辐射防护药研制第二阶段——用大型实验动物验证效价时,微核测定方法是否仍然适用,这是一个需要进一步研究的问题。通常,我们是以致死剂量或亚致死剂量照射狗的30天活存率为主要指标,辅以某些血液学指标如白细胞总数测定和急性放射病临床症状观察等,然后对辐射防护药的效价加以综合的评价。但这些指标有的生理波动比较大,有的观察时间较长,有的有明显的个体差异。因此寻找灵敏、简便、生物学意义比较明确的新指标有其一定的意义。染色体畸变分析在一定程度上可以满足上述要求,但方法繁杂,不适合大规模动物实验的实际需要,而且常用的实验动物狗的核型特点是染色
Our work shows that the screening of mouse bone marrow nucleated cell micronuclei assay for radioprotective drugs is a sensitive and simple new indicator. The second phase of the development of radioprotective drugs - verification of titer with large laboratory animals, micronucleus test method is still applicable, which is a need for further study. Generally, we use the lethal or sublethal dose of 30-day survival rate of dogs as the main indicator, supplemented by certain hematological indicators such as white blood cell count and clinical observation of acute radiation sickness symptoms, and then the radiation protective drug potency To be comprehensive evaluation. However, some of these indicators of physiological fluctuations relatively large, and some observation time longer, and some obvious individual differences. Therefore, it is of certain significance to find a new indicator that is sensitive, simple and has a clear biological meaning. Chromosome aberration analysis to some extent to meet the above requirements, but the method is complex, not suitable for the actual needs of large-scale animal experiments, and commonly used experimental animals karyotype is characterized by staining